A5022760863- Pain Mechanisms and Treatments
- Neuropeptides and Animal Physiology
- Cannabis and Cannabinoid Research
- Neurotransmitter Receptor Influence on Behavior
- Pain Management and Opioid Use
- Opioid Use Disorder Treatment
- Neuroscience and Neuropharmacology Research
- Receptor Mechanisms and Signaling
- Musculoskeletal pain and rehabilitation
- Stress Responses and Cortisol
- HIV, Drug Use, Sexual Risk
- Primary Care and Health Outcomes
- Pharmacological Receptor Mechanisms and Effects
- COVID-19 and Mental Health
- Neuroinflammation and Neurodegeneration Mechanisms
- Hormonal and reproductive studies
- Regulation of Appetite and Obesity
- Nursing Roles and Practices
- Infant Health and Development
- Obsessive-Compulsive Spectrum Disorders
- Poisoning and overdose treatments
- Psychedelics and Drug Studies
- Substance Abuse Treatment and Outcomes
- Pain Management and Placebo Effect
- GABA and Rice Research
Columbia University
2018-2024
New York State Psychiatric Institute
2020-2022
Seattle University
2022
New York Psychoanalytic Society and Institute
2020-2021
Yale University
2015-2020
Columbia University Irving Medical Center
2018-2020
VA Connecticut Healthcare System
2015-2020
Research Foundation For Mental Hygiene
2020
College of New Rochelle
2017
City University of New York
2008-2014
Cannabis use disorder (CUD) is widespread, and there no pharmacotherapy to facilitate its treatment. AEF0117, the first of a new pharmacological class, signaling-specific inhibitor cannabinoid receptor 1 (CB1-SSi). AEF0117 selectively inhibits subset intracellular effects resulting from Δ9-tetrahydrocannabinol (THC) binding without modifying behavior per se. In mice non-human primates, decreased self-administration THC-related behavioral impairment producing significant adverse effects....
Fibromyalgia is a poorly understood, chronically disabling pain syndrome. While research has focused on its clinical presentation and treatment, less known about fibromyalgia's epidemiology in real-world healthcare systems. Gender differences have been difficult to study because relatively few males are diagnosed with fibromyalgia.Veterans Health Administration (VHA) patients fibromyalgia nationwide FY 2012 were compared Veterans other diagnoses sociodemographic characteristics, medical...
Aims Preclinical studies demonstrate that cannabidiol (CBD) elicits an antinociceptive response in animal models of neuropathic pain; humans, limited data are available to support such analgesic effects. Few have examined CBD's effects when administered without other compounds, and little is known regarding dose‐dependent noncannabis users. Methods This double‐blind, placebo‐controlled, within‐subject outpatient clinical laboratory study sought determine the effects, abuse liability, safety...
Background Preclinical data implicate the endocannabinoid system in pathology underlying obsessive-compulsive disorder (OCD), while survey have linked OCD symptoms to increased cannabis use. Cannabis products are increasingly marketed as treatments for anxiety and other OCD-related symptoms. Yet, few studies tested acute effects of on psychiatric humans. Methods We recruited 14 adults with prior experience using enter a randomized, placebo-controlled, human laboratory study compare...
N-Methyl-D-aspartate receptor antagonists reverse hyperalgesia during morphine infusion in male mice only. Because the melanocortin-1 can act as a female-specific counterpart to N-methyl-D-aspartate receptors kappa-opioid analgesic mechanisms, authors assessed contribution of sex-specific mechanisms underlying hyperalgesia.The tail-withdrawal test was used compare nociceptive responses and female C57BL/6J (B6) with those C57BL/6J-Mc(1r(e/e)) mice, spontaneous mutants B6 background lacking...
Previous data indicate that morphine-6beta-glucuronide (M6G), a morphine metabolite with analgesic properties, can paradoxically increase pain sensitivity in mice and humans. The authors tested humans for M6G hyperalgesia assessed the contribution of N-methyl-D-aspartate receptor activity mice.Nociception after acute injection (10 mg/kg) chronic infusion (1.6 mg/kg per 24 h) or saline was assayed using tail-withdrawal test CD-1 implanted pellets containing opioid antagonist naltrexone...
Background The objective of this study was to assess ethanol's (EtOH's) effects on capsaicin-induced hyperalgesia in healthy participants. Specifically, we investigated the change area following 3 interventions: intravenous EtOH at 2 targeted breath alcohol concentrations (BrAC), or placebo. Methods Eighteen participants participated test days a randomized order. Each day, received an intradermal capsaicin injection volar surface forearm, followed by either infusion high concentration...
Opioid-induced hyperalgesia (OIH) is a paradoxical increase in pain perception that may manifest during opioid treatment. For morphine, the metabolite morphine-3-glucuronide (M3G) commonly believed to underlie this phenomenon. Here, three separate studies, we empirically assess role of M3G morphine-induced hyperalgesia. In first study, CD-1 mice injected with morphine (15 mg/kg subcutaneously) after pretreatment receptor antagonist naltrexone (NTX) mg/kg) showed tail withdrawal latency...
Chronic pain management is a growing focus of attention, in part because concern over excessive use opioids for treatment chronic noncancer pain. In the Veterans Health Administration (VHA), specialty clinics have been established to address needs patients with challenging issues. The current study identified characteristics such national sample VHA service users fiscal year 2012.Bivariate analyses compared diagnosed who visited clinic those did not on sociodemographic characteristics,...
Abstract There are no FDA‐approved treatments for cannabis use disorder (CUD). Preclinical research has shown that the 5HT‐2C agonist lorcaserin attenuates cue‐induced reinstatement of THC seeking and self‐administration. The goal this placebo‐controlled, counterbalanced, within‐subject human laboratory study was to examine lorcaserin's effects on intoxication Lorcaserin (10 mg BID) administered during one two 13‐day inpatient phases placebo other; each phase separated by ≥7 days washout....
Past investigations assessing the effects of thiopental on pain are conflicting. Although several studies demonstrate hyperalgesia as a result barbiturate administration, others show analgesia. Our objective was to assess an infusion GABAA agonist thiopental, compared with placebo, in healthy participants two subjective experimental paradigms: noxious electrical stimulation and intradermal capsaicin.For stimulation, milliamps required achieve threshold tolerance were recorded, percent change...